Literature DB >> 29594935

Diabetes Mellitus as a Risk Factor for Parkinson's Disease: a Molecular Point of View.

Alice Biosa1, Tiago F Outeiro2,3,4, Luigi Bubacco1, Marco Bisaglia5.   

Abstract

Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by elevated concentrations of glucose in the blood. The chronic hyperglycemic state accounts for most of the vascular complications associated to the disease and the prevalent mechanism proposed is related to the glycating chemistry mediated by methylglyoxal (MG), which accumulates in T2DM. In recent years, a higher risk of Parkinson's disease (PD) onset in people affected by T2DM has become evident, but the molecular mechanisms underlying the interplay between T2DM and PD are still unknown. The oxidative chemistry of dopamine and its reactivity towards the protein α-Synuclein (aS) has been associated to the pathogenesis of PD. Recently, aS has also been described to interact with MG. Interestingly, MG and the dopamine oxidation products share both structural similarity and chemical reactivity. The ability of MG to spread over the site of its production and react with aS could represent the rationale to explain the higher incidence of PD in T2DM-affected people and may open opportunities for the development of novel strategies to antagonize the raise of PD.

Entities:  

Keywords:  DOPAL; Dopamine; Methylglyoxal; Parkinson’s disease; Type 2 diabetes mellitus; α-Synuclein

Mesh:

Substances:

Year:  2018        PMID: 29594935     DOI: 10.1007/s12035-018-1025-9

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  93 in total

Review 1.  Metformin: from mechanisms of action to therapies.

Authors:  Marc Foretz; Bruno Guigas; Luc Bertrand; Michael Pollak; Benoit Viollet
Journal:  Cell Metab       Date:  2014-10-30       Impact factor: 27.287

2.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

3.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

4.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Authors:  Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

Review 5.  Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Authors:  Dena G Hernandez; Xylena Reed; Andrew B Singleton
Journal:  J Neurochem       Date:  2016-04-18       Impact factor: 5.372

Review 6.  Methylglyoxal toxicity in mammals.

Authors:  M P Kalapos
Journal:  Toxicol Lett       Date:  1994-07       Impact factor: 4.372

Review 7.  Dicarbonyls and glyoxalase in disease mechanisms and clinical therapeutics.

Authors:  Naila Rabbani; Mingzhan Xue; Paul J Thornalley
Journal:  Glycoconj J       Date:  2016-07-12       Impact factor: 2.916

8.  DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.

Authors:  N Plotegher; G Berti; E Ferrari; I Tessari; M Zanetti; L Lunelli; E Greggio; M Bisaglia; M Veronesi; S Girotto; M Dalla Serra; C Perego; L Casella; L Bubacco
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

9.  Measurement of methylglyoxal by stable isotopic dilution analysis LC-MS/MS with corroborative prediction in physiological samples.

Authors:  Naila Rabbani; Paul J Thornalley
Journal:  Nat Protoc       Date:  2014-07-24       Impact factor: 13.491

10.  DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease.

Authors:  L Zondler; L Miller-Fleming; M Repici; S Gonçalves; S Tenreiro; R Rosado-Ramos; C Betzer; K R Straatman; P H Jensen; F Giorgini; T F Outeiro
Journal:  Cell Death Dis       Date:  2014-07-24       Impact factor: 8.469

View more
  17 in total

1.  Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.

Authors:  Vinita G Chittoor-Vinod; Steffany Villalobos-Cantor; Hanna Roshak; Kelsey Shea; Leire Abalde-Atristain; Ian Martin
Journal:  J Neurosci       Date:  2020-06-30       Impact factor: 6.167

2.  Thioredoxin-Interacting Protein (TXNIP) Regulates Parkin/PINK1-mediated Mitophagy in Dopaminergic Neurons Under High-glucose Conditions: Implications for Molecular Links Between Parkinson's Disease and Diabetes.

Authors:  Cun-Jin Su; Zhu Shen; Ru-Xiao Cui; Ya Huang; De-Lai Xu; Feng-Lun Zhao; Jie Pan; Ai-Ming Shi; Tong Liu; Yun-Li Yu
Journal:  Neurosci Bull       Date:  2020-01-14       Impact factor: 5.203

3.  Interactive Association Between Intronic Polymorphism (rs10506151) of the LRRK2 Gene and Type 2 Diabetes on Neurodegenerative Diseases.

Authors:  Mei-Hsuen Huang; Yu-Fan Liu; Oswald Ndi Nfor; Shu-Yi Hsu; Wei-Yong Lin; Yuan-Shiun Chang; Yung-Po Liaw
Journal:  Pharmgenomics Pers Med       Date:  2021-07-13

Review 4.  Impaired dopamine metabolism in Parkinson's disease pathogenesis.

Authors:  Anna Masato; Nicoletta Plotegher; Daniela Boassa; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2019-08-20       Impact factor: 14.195

5.  Downregulated Dopamine Receptor 2 and Upregulated Corticotrophin Releasing Hormone in the Paraventricular Nucleus Are Correlated With Decreased Glucose Tolerance in Rats With Bilateral Substantia Nigra Lesions.

Authors:  Li Zhou; Xue-Rui Ran; Feng Hong; Guang-Wen Li; Jin-Xia Zhu
Journal:  Front Neurosci       Date:  2019-07-23       Impact factor: 4.677

Review 6.  Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes.

Authors:  Valerio Caputo; Andrea Termine; Claudia Strafella; Emiliano Giardina; Raffaella Cascella
Journal:  World J Diabetes       Date:  2020-05-15

7.  Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose.

Authors:  Zubeyir Elmazoglu; Marta Soltesova Prnova; Abel Santamaria; Milan Stefek; Cimen Karasu
Journal:  Neurotox Res       Date:  2020-11-04       Impact factor: 3.911

8.  Attenuated Postprandial GLP-1 Response in Parkinson's Disease.

Authors:  Richard A Manfready; Phillip A Engen; Leo Verhagen Metman; Gabriella Sanzo; Christopher G Goetz; Deborah A Hall; Christopher B Forsyth; Shohreh Raeisi; Robin M Voigt; Ali Keshavarzian
Journal:  Front Neurosci       Date:  2021-07-02       Impact factor: 4.677

Review 9.  The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease.

Authors:  Julia L Y Cheong; Eduardo de Pablo-Fernandez; Thomas Foltynie; Alastair J Noyce
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

10.  A Network-Based Bioinformatics Approach to Identify Molecular Biomarkers for Type 2 Diabetes that Are Linked to the Progression of Neurological Diseases.

Authors:  Md Habibur Rahman; Silong Peng; Xiyuan Hu; Chen Chen; Md Rezanur Rahman; Shahadat Uddin; Julian M W Quinn; Mohammad Ali Moni
Journal:  Int J Environ Res Public Health       Date:  2020-02-06       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.